2024
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpointTorsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure
Krim S, Anand S, Greene S, Chen A, Wojdyla D, Vilaro J, Haught H, Herre J, Eisenstein E, Anstrom K, Pitt B, Velazquez E, Mentz R. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure. JAMA Cardiology 2024, 9: 182-188. PMID: 37955908, PMCID: PMC10644243, DOI: 10.1001/jamacardio.2023.4776.Peer-Reviewed Original ResearchDe novo heart failureNovo heart failureChronic heart failureHeart failurePatient-reported outcomesCause mortalityHF typeKansas City Cardiomyopathy Questionnaire clinical summary scoreHigher glomerular filtration rateSignificant differencesHeart Failure TrialGlomerular filtration rateClinical summary scoreDiuretic strategyFirst rehospitalizationCause hospitalizationNew onsetTotal hospitalizationsClinical characteristicsClinical profileEjection fractionLoop diureticsFailure TrialHospitalization outcomesNatriuretic peptide
2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapyEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2011
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart B, Mascette AM, Braunwald E, O'Connor CM. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal Of Medicine 2011, 364: 797-805. PMID: 21366472, PMCID: PMC3412356, DOI: 10.1056/nejmoa1005419.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedArea Under CurveCreatinineDiureticsDouble-Blind MethodDrug Administration ScheduleDyspneaFemaleFurosemideHeart FailureHumansInfusions, IntravenousInjections, IntravenousIntention to Treat AnalysisKaplan-Meier EstimateMaleMiddle AgedSodium Potassium Chloride Symporter InhibitorsConceptsAcute decompensated heart failureDecompensated heart failurePatient global assessmentHeart failureCreatinine levelsContinuous infusionHigh-dose strategyGlobal assessmentRenal functionMean changeLow doseHigh doseSignificant differencesCoprimary end pointsSerum creatinine levelsHigh-dose groupLow-dose strategyVisual analog scaleComparison of BolusDiuretic strategyDiuretic therapyTransient worseningGreater diuresisDose adjustmentLoop diuretics